News coverage about Regeneron Pharmaceuticals (NASDAQ:REGN) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7168815713537 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- MayTech Global Investments LLC Purchases New Holdings in Regeneron Pharmaceuticals Inc (REGN) (americanbankingnews.com)
- Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Eaton Vance Management (americanbankingnews.com)
- Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Bbva Compass Bancshares Inc. (americanbankingnews.com)
- Baird Financial Group Inc. Has $5.92 Million Position in Regeneron Pharmaceuticals Inc (REGN) (americanbankingnews.com)
- Regeneron Pharmaceuticals (REGN) Stock Rating Lowered by Canaccord Genuity (americanbankingnews.com)
REGN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $491.00 to $479.00 and set a “market perform” rating for the company in a report on Thursday, November 9th. Finally, Argus lowered their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a report on Thursday, December 28th. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $450.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the previous year, the firm posted $3.04 EPS. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. analysts predict that Regeneron Pharmaceuticals will post 19.2 EPS for the current year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.80% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.